共 47 条
[1]
Martin M.(2005)Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302-2313
[2]
Pienkowski T.(1997)Cost-utility analysis of taxane therapy Am J Health Syst Pharm 54 S11-15
[3]
Mackey J.(1997)Cost utility in second-line metastatic breast cancer Pharmacoeconomics 11 492-497
[4]
Yee G.C.(1996)A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine Pharmacoeconomics 10 504-521
[5]
Berdeaux G.(2003)Population-based phar macoeconomic model for adopting capecitabine/docetaxel combination treatment for anthra-cycline-pretreated metastatic breast cancer Oncologist 8 232-240
[6]
Hurteloup P.(1983)The Markov process in medical prognosis Med Decis Making 3 419-458
[7]
Launois R.(1997)Primer on medical decision analysis: Part 5. Working with Markov processes Med Decis Making 17 152-159
[8]
Reboul-Marty J.(1998)An introduction to Markov modelling for economic evaluation Pharmacoeconomics 13 397-409
[9]
Henry B.(2005)Impact of adjuvant chemotherapy with docetaxel for early breast cancer: cost-effectiveness analysis (CEA) of a docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in France Value Health 8 A36-A37
[10]
Bonneterre J.(2006)Cost-effectiveness of TAC versus FAC for the treatment of node positive breast cancer in the adjuvant setting Value Health 9 A208-A393